KROS-101 / Kairos Pharma - LARVOL DELTA

Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity. (ASCO 2025) - "KROS 101 is a GITR ligand agonist that increases T cell proliferation and increased cytotoxicity and reduces the T reg population more effectively than TRX 518 which is a therapeutic GITR antibody that was in clinical trial."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD4 • CD8 • HAVCR2 • IFNG • TIGIT • TNFA

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Businesswire) - "In the presentation...the study authors presented their findings that demonstrated KROS 101’s capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study authors also indicated their study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, enhancing the immune response by boosting cytokine production and tumor cancer cell killing. In addition, the study found that KROS101 reduced T reg-mediated suppression by reducing T reg populations, which reverses immune system suppression and enhances effector T cell activity."

Preclinical • Oncology

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Businesswire) - "The poster is titled, 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,' and will be presented on June 2."

Preclinical • Oncology

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events (Businesswire) - "Kairos Pharma...highlights activity at recent scientific conferences and announces participation in future events. Highlights include: March 12, 2025 - Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, 'Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment'."

Preclinical • Oncology

KROS 101: A Next Generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor environment (Businesswire) - "Kairos Pharma...announced that the company presented preclinical data on its investigational compounds...during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference....In the presentation...study authors demonstrated that KROS significantly inhibited tumor growth in a preclinical melanoma model. The same team of scientists also showed that KROS 101 increased the proliferation of helper and cytotoxic T cells (CD4+ and CD8+), while decreasing T reg cell growth in a melanoma model. Further, T cells treated with KROS 101 showed cytotoxicity against glioblastoma cell lines and glioma cancer cells..."

Preclinical • Glioblastoma • Glioma • Melanoma

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma (Businesswire) - "Kairos Pharma...announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101....The results...demonstrated that KROS 101 is a potent GITR ligand agonist that enhances T cell infiltration, proliferation, and ability to kill cancer cells in mouse models of melanoma and in human glioblastoma in vitro, while effectively reducing T reg-mediated suppression. KROS 101 showed significant activity in enabling T cell proliferation and killing of melanoma tumors in vivo as well as glioblastoma tumor in vitro."

Preclinical • Glioblastoma • Melanoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 (Businesswire) - "Kairos Pharma Ltd...announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii."

Preclinical • Solid Tumor

Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire) - "The Company intends to use the net proceeds from the offering to fund its Phase 1 trial in lung cancer and Phase 2 trial in prostate cancer for its lead product candidate ENV 105, designed to reverse resistance to standard of care drugs. The proceeds will also advance preclinical candidates, including KROS 101, a small molecule agonist for the GITR ligand, designed to promote T cell growth and cytotoxic function against cancer."

Commercial • Genito-urinary Cancer • Oncology • Prostate Cancer